Abstract
It is not known whether the HER2 status of malignant CSF cells coincides with that of the original breast carcinoma cells. We investigated whether CSF cytology specimens were suitable to evaluate HER2 status by fluorescence in situ hybridization (FISH) in patient with leptomeningeal metastasis (LM). Both formalin-fixed paraffin-embedded (FFPE) breast cancer tissue and liquid based CSF cytology specimens were evaluated for HER2 status in 16 patients with LM. We evaluated HER2 gene amplification using FISH on destained CSF cytology slides containing a minimum of 20 malignant cells per slide, and compared these with the HER2 status by immunohistochemistry (IHC) or FISH in FFPE tissues. HER2 was considered positive when the HER2:CEP17 ratio was >or=2.0 or IHC 3+. Of 16 cases, four were HER2 positive and 12 were HER2 negative by FISH analysis in CSF cytology. All CSF-positive cases were HER2 positive by IHC in FFPE tissue. Of 12 HER2 FISH-negative cases in CSF cytology, 10 were HER2 negative (IHC 0 or 1+) and two were IHC 2+ in FFPE tissue. Two IHC 2+ cases had HER2:CEP17 ratios of 1.27 and 2.1, respectively, by FISH in FFPE tissue. As a result, the HER2 status concordance rate between metastatic breast cancer cells in CSF and FFPE ...Continue Reading
References
Feb 15, 1982·Cancer·W R WasserstromJ B Posner
Mar 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S A GrossmanD S Ettinger
Apr 2, 1998·Journal of Neuro-oncology·M C Chamberlain
Jan 30, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E ShmueliM Inbar
Feb 11, 2004·Japanese Journal of Clinical Oncology·Dae-Young KimNoe Kyeong Kim
Jul 22, 2004·British Journal of Cancer·A J ClaytonA M Wardley
Sep 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy U LinEric P Winer
Sep 2, 2006·The Lancet Oncology·Christian PlatiniSabine Walter
Dec 13, 2006·Anti-cancer Drugs·Hans-Joachim StemmlerVolker Heinemann
Feb 21, 2007·Journal of Neuro-oncology·Halina RudnickaMagdalena Murawska
Jul 31, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I H ParkK H Shin
Aug 12, 2008·Anti-cancer Drugs·Hans-Joachim StemmlerVolker Heinemann
Oct 11, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O MirF Goldwasser
Nov 7, 2008·Cancer Chemotherapy and Pharmacology·Mariantonietta ColozzaPiero Floridi
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido SauterMichael F Press
Feb 19, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C FerrarioL C Panasci
Jul 15, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C LiedtkeA M Gonzalez-Angulo
Citations
Dec 12, 2012·Japanese Journal of Clinical Oncology·Koji ArihiroYuko Taira
Mar 5, 2011·Fluids and Barriers of the CNS·Cody L WestonJames R Connor
Oct 8, 2014·Acta Neuropathologica·Anna Sophie BerghoffMatthias Preusser
Feb 15, 2016·Breast Cancer Research and Treatment·Pooja MurthyN Lynn Henry
Jul 14, 2016·Cancer Metastasis Reviews·C YeungA Arnaout
Feb 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luigi CavannaGiuseppe Civardi
May 30, 2013·Surgical Neurology International·Emilie Le RhunMarc C Chamberlain
Jun 19, 2019·Breast Cancer Research and Treatment·Nicholas B FiguraKamran A Ahmed
Oct 22, 2013·Cancer Research·Mark Jesus M MagbanuaJohn W Park
Jul 20, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Adam M BrufskyDenise A Yardley
Jul 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Le RhunUNKNOWN EANO Executive Board and ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org